💥 Dragon Pharma

PNC-27

✔️ Substance: PNC-27
✔️ Price For: Vial 5 mg
✔️ Brand: Dragon Pharma

Out of stock

Dragon Pharma PNC-27

IDENTITYCompoundPNC-27
BrandDragon Pharma
Strength5 mg
FormVial
ClassResearch Peptide

PEPTIDE PROFILETypep53-derived Peptide
StructureSynthetic Peptide
TargetMDM2 / p53 Pathway
ResearchCellular Biology
StatusInvestigational Compound

PHARMACOLOGYMechanismp53 Pathway Modulation
ActivityExperimental
AdministrationSubcutaneous Research Use
Human DataLimited
Clinical ApprovalNot Approved

STORAGE & PACKAGEBrandDragon Pharma
Package5 mg Vial
StorageControlled Refrigeration
ProtectionLight & Moisture
StabilityFollow Manufacturer Data

ADMINISTRATION UsageExperimental Research
Administration Typically Investigated by Injection
DosageNo Established Human Dose
FrequencyResearch Dependent
DurationNo Approved Protocol

BODYBUILDING USAGECategoryResearch Peptide
Muscle GrowthIndirect Research Interest
RecoveryExperimental Cellular Studies
Fat LossNo Established Effect
PCTNot Applicable

USAGE PROFILEPurposeScientific Research
Usage TimeNo Approved Timeline
Cycle LengthNo Clinical Cycle
MonitoringLaboratory Evaluation
RecoveryNo Hormonal Suppression

SAFETY PROFILEHuman SafetyInsufficient Data
ToxicityNot Fully Established
Hormonal ImpactNot Comparable to Steroids
MonitoringRequired in Research
PCTNot Required

MECHANISM OF ACTIONPrimary Pathwayp53 Regulation
InteractionMDM2 Binding Research
Cellular RoleApoptosis Regulation
Research FieldCancer Biology
Protein Targetp53 Tumor Suppressor

PHARMACOKINETICSHalf-LifeNot Established
AbsorptionResearch Dependent
MetabolismPeptide Degradation Pathways
DistributionExperimental Data
ClearanceNot Fully Defined

CONTRAINDICATIONSPregnancyAvoid Research Use
Medical ConditionsProfessional Assessment
Drug InteractionUnknown
Long-Term DataUnavailable
MonitoringRecommended

CHEMICAL PROFILECompoundPNC-27 Peptide
Classp53 Derived Peptide
FormulaResearch Specific Sequence
Molecular WeightSequence Dependent
CASNot Established

OVERVIEW

Dragon Pharma PNC-27 5 mg is a synthetic research peptide derived from a region of the human p53 protein. PNC-27 has been investigated in cellular biology studies because of its interaction with the MDM2-p53 pathway, which plays an important role in regulation of cellular processes. Unlike anabolic steroids, growth hormone compounds, or traditional bodybuilding peptides, PNC-27 is not an approved performance-enhancing medication and has no established bodybuilding dosage protocol.

POTENTIAL BENEFITS

Research interest in p53 pathway modulation
Studied interaction with MDM2 protein
Investigated in cellular biology models
Potential research value in apoptosis studies
Provides insight into tumor suppressor mechanisms
Useful for laboratory peptide research

POTENTIAL RISKS

Limited human safety information
No approved medical indication
No established long-term safety profile
Unknown effects from non-clinical use
Research-only compound limitations
Possible injection-related risks

PERFORMANCE PROFILE

Muscle Gain

15%

Strength

10%

Recovery

25%

Fat Loss

10%

Research Activity

80%

WHAT IS DRAGON PHARMA?

Dragon Pharma is a pharmaceutical-style brand name commonly associated with performance and research-oriented products marketed toward bodybuilding and fitness communities. Products carrying this branding are frequently discussed in athletic environments, although individual compounds must always be evaluated according to their own scientific classification, regulatory status, and available research data.

For research compounds such as PNC-27, scientific evaluation should focus on compound identity, laboratory information, storage requirements, and available published research rather than bodybuilding claims.

WHY CHOOSE DRAGON PHARMA

Dragon Pharma products are selected by some research and bodybuilding communities because of brand recognition, product presentation, and availability of different specialized compounds. When evaluating any pharmaceutical or research product, important factors include transparent labeling, proper storage conditions, quality control procedures, and responsible handling.

For investigational compounds such as PNC-27, scientific documentation and responsible research practices remain more important than performance expectations.

CONCLUSION

Dragon Pharma PNC-27 5 mg is an experimental peptide compound associated with research involving the p53-MDM2 cellular pathway. Unlike anabolic steroids or growth hormone products, PNC-27 does not have established bodybuilding applications, approved dosing schedules, or recognized performance-enhancing effects.

Current scientific interest is focused on molecular biology research, including cellular signaling mechanisms and peptide interactions. Available evidence remains primarily laboratory-based, making careful interpretation essential.

Interest among advanced research communities is related to its experimental mechanism rather than direct anabolic activity. Current scientific investigation focuses on molecular interactions, cellular signaling, and potential therapeutic applications.

There is no scientifically validated bodybuilding cycle, dosage (mg/week), administration schedule, usage duration, or PCT requirement for PNC-27. Any discussion of use should remain within a research and educational context.

DISCLAIMER

This information is provided for educational and scientific reference purposes only. PNC-27 is an investigational peptide and is not approved as a medication or bodybuilding performance compound. This page does not provide medical advice, treatment recommendations, or instructions for non-approved human use.